Punjab And Haryana HC Notice To Centre On Petition Against Misuse Of Oxytocin

Chandigarh: The Punjab and Haryana High Court today sought response from the Union and State government in PIL seeking implementation of Prevention of Cruelty to Animals Act, 1960 (Resignation of Cattle Premises, Rules 1978) in dairy farms of Chandigarh as well as neighbouring villages.

Acting Chief Justice G.S. Sandhwalia and Justice Lapita Banerji issued notice to Union of India, Ministry of Department of Fisheries, Municipal Corporation of Chandigarh and other authorities.

Some residents of Chandigarh have moved High Court stating that the “Dairy Farmers are using unauthorised drugs like Oxytocin” and cattle are kept in inadequate living condition in Chandigarh and nearby villages of the two states.

The Chandigarh Police and concerned Respondents had adopted a casual approach for not taking any action despite the fact an offence Us 12 of Cruelty to Animals Act, 1960 and 429 of Indian Penal Code, 1860 is made out qua the Dairy Farmers,” the plea adds.

The plea also seeks directions on respondents to urgently take necessary steps to stop alleged animal cruelty at the Dairy farms and to follow the minimum standards of housing laid down by Indian Council of Agricultural Research in National Code of Practices for Management of Dairy Animals in India, especially, keeping in view the provisions of Prevention of Cruelty to Animals Act.

The matter is listed for July 16, for further consideration.

Related Posts

  • Pharma
  • June 24, 2025
  • 91 views
Glenmark Pharma launches TEVIMBRA in India

Glenmark Pharmaceuticals announced that it had launched TEVIMBRA (tislelizumab) in India after receiving approval from the Central Drugs Standard Control Organization (CDSCO). The drug is a specially designed anti-PD-1 monoclonal…

  • Pharma
  • June 24, 2025
  • 91 views
India’s herbal and ayurvedic OTC market set to outpace global growth

New Delhi: India’s herbal and ayurvedic OTC (over the counter) market is expected to grow at a CAGR of 6.5 per cent, from $69 million in 2025 to $118 million…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Glenmark Pharma launches TEVIMBRA in India

Glenmark Pharma launches TEVIMBRA in India

India’s herbal and ayurvedic OTC market set to outpace global growth

India’s herbal and ayurvedic OTC market set to outpace global growth

Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug